CN106170299A - 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 - Google Patents

用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 Download PDF

Info

Publication number
CN106170299A
CN106170299A CN201580015746.2A CN201580015746A CN106170299A CN 106170299 A CN106170299 A CN 106170299A CN 201580015746 A CN201580015746 A CN 201580015746A CN 106170299 A CN106170299 A CN 106170299A
Authority
CN
China
Prior art keywords
cell
cells
antibody
agonist
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580015746.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·G·恩格勒曼
Y·卡米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN106170299A publication Critical patent/CN106170299A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201580015746.2A 2014-01-22 2015-01-22 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 Pending CN106170299A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461930386P 2014-01-22 2014-01-22
US61/930,386 2014-01-22
US201462066574P 2014-10-21 2014-10-21
US62/066,574 2014-10-21
PCT/US2015/012511 WO2015112749A2 (en) 2014-01-22 2015-01-22 Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy

Publications (1)

Publication Number Publication Date
CN106170299A true CN106170299A (zh) 2016-11-30

Family

ID=53682123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015746.2A Pending CN106170299A (zh) 2014-01-22 2015-01-22 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物

Country Status (8)

Country Link
US (2) US20160340439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3096787A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017507922A (cg-RX-API-DMAC7.html)
KR (1) KR20160106170A (cg-RX-API-DMAC7.html)
CN (1) CN106170299A (cg-RX-API-DMAC7.html)
AU (1) AU2015209277B2 (cg-RX-API-DMAC7.html)
CA (1) CA2937499A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015112749A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110396498A (zh) * 2018-04-25 2019-11-01 重庆市畜牧科学院 体外活化记忆性b细胞成浆细胞的方法
CN110628621A (zh) * 2019-10-28 2019-12-31 合肥中科干细胞再生医学有限公司 一种获得肿瘤特异性t细胞的设备和方法
CN112689511A (zh) * 2018-07-23 2021-04-20 安吉尼科分子传输公司 包含细菌源微细胞的组合物及其使用方法
CN113613672A (zh) * 2019-01-28 2021-11-05 阿姆弗拉公司 用于治疗胰腺癌的药物组合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200079860A1 (en) * 2015-08-06 2020-03-12 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
US11083751B2 (en) * 2016-02-26 2021-08-10 Vib Vzw Tumor-associated dendritic cell preparations and uses thereof
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
US12171803B2 (en) 2017-04-12 2024-12-24 Memgen, Inc. Methods of CD40 and toll like receptor immune activation
WO2019189780A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
EP4724498A2 (en) * 2023-06-09 2026-04-15 The Regents of the University of California Methods for identifying and correcting tumor humoral immune dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
WO2010132622A2 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
WO2012170072A1 (en) * 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
CN103328005A (zh) * 2010-08-13 2013-09-25 贝勒研究院 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2002066044A2 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
SG189730A1 (en) * 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
WO2010132622A2 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
CN103328005A (zh) * 2010-08-13 2013-09-25 贝勒研究院 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂
WO2012170072A1 (en) * 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JORGE SCHETTINI等: "Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity", 《CANCER IMMUNOL IMMUNOTHER》 *
LIM CHWEE MING等: "《TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR + head and neck cancer cells》", 《ONCOIMMUNOLOGY》 *
WANG SHANGZI等: "《Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment》", 《CANCER IMMUNOLOGY IMMUNOTHERAPY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110396498A (zh) * 2018-04-25 2019-11-01 重庆市畜牧科学院 体外活化记忆性b细胞成浆细胞的方法
CN112689511A (zh) * 2018-07-23 2021-04-20 安吉尼科分子传输公司 包含细菌源微细胞的组合物及其使用方法
US12414968B2 (en) 2018-07-23 2025-09-16 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CN113613672A (zh) * 2019-01-28 2021-11-05 阿姆弗拉公司 用于治疗胰腺癌的药物组合物
CN110628621A (zh) * 2019-10-28 2019-12-31 合肥中科干细胞再生医学有限公司 一种获得肿瘤特异性t细胞的设备和方法
CN110628621B (zh) * 2019-10-28 2023-12-22 合肥中科干细胞再生医学有限公司 一种获得肿瘤特异性t细胞的设备和方法

Also Published As

Publication number Publication date
AU2015209277A1 (en) 2016-08-11
EP3096787A4 (en) 2018-02-07
EP3096787A2 (en) 2016-11-30
US20210024649A1 (en) 2021-01-28
KR20160106170A (ko) 2016-09-09
AU2015209277B2 (en) 2020-09-03
JP2017507922A (ja) 2017-03-23
CA2937499A1 (en) 2015-07-30
WO2015112749A2 (en) 2015-07-30
WO2015112749A3 (en) 2015-11-12
US20160340439A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
US20210024649A1 (en) Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy
JP7325959B2 (ja) 腫瘍特異的細胞の枯渇のための抗CD25 FCγ受容体二重特異性抗体
AU2001267780B2 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
JP2022502037A (ja) コラーゲンに局在化される免疫調節分子およびその方法
US8597946B2 (en) Enhanced dendritic cells for cancer immunotherapy
TW201803994A (zh) 嵌合抗原和t細胞受體及使用方法
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
JP2013525496A (ja) ヒトcd8+t細胞の樹状細胞免疫受容体(dcir)媒介クロスプライミング
JP7688025B2 (ja) 抗cd19抗体及びガンマデルタt細胞を含む抗腫瘍併用療法
KR20220005075A (ko) 키메라 항원 수용체 면역요법의 투여 방법
WO2016064899A1 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
KR20240103033A (ko) 키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
JP7670614B2 (ja) 抗原提示好中球由来樹状細胞およびその使用方法
JP2026048806A (ja) 細胞傷害性t細胞耐性腫瘍を治療するための組成物および方法
WO2025242193A1 (zh) 博来霉素作为免疫增强剂的用途
US8945566B2 (en) Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease
US20250057949A1 (en) T cell therapy with vaccination as a combination immunotherapy against cancer
Στραβοκεφάλου The role of cellular immunity in the treatment of cancer
EP4601682A1 (en) Methods and compositions for improving response to immunotherapy
McKenzie et al. Targeting lymphocyte Peyer's patch adhesion molecule-1: A relay approach to gut immunization
Rotte et al. Promising immunotherapeutic approaches in clinical trials
WO2012018260A1 (en) Epidermal growth factor receptor targeted immune therapy
Montorfani Activation sélective de la signalisation interleukine-2/interleukine-15 dans le microenvironnement tumoral par des paires d’anticorps bispécifiques
Dylan et al. Optimization of T-cell receptor–modified T cells for cancer
Nguyen et al. Basic Science of Oncology,(McGraw-Hill International Editions)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161130